Yoshisue K[au] - Search Results

Year	Number of Results
1996	1
2000	4
2001	2
2008	1
2009	1
2010	1
2011	1
2012	1
2013	1
2014	3
2015	2
2016	1
2017	3
2018	2
2019	2
2021	1
2022	1
2024	0

1

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.

Araki H, Takenaka T, Takahashi K, Yamashita F, Matsuoka K, Yoshisue K, Ieiri I. Araki H, et al. Among authors: yoshisue k. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):604-615. doi: 10.1002/psp4.12747. Epub 2021 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34951129 Free PMC article.

2

Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.

Yasui H, Kawakami T, Kashiwagi H, Mori K, Omae K, Kasai J, Yoshisue K, Kawahira M, Tsushima T, Machida N, Fukutomi A, Yamaguchi K. Yasui H, et al. Among authors: yoshisue k. Int J Clin Oncol. 2019 Jun;24(6):660-665. doi: 10.1007/s10147-018-01387-6. Epub 2019 Apr 22. Int J Clin Oncol. 2019. PMID: 31011915 Free PMC article.

3

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy.

Yano W, Yokogawa T, Wakasa T, Yamamura K, Fujioka A, Yoshisue K, Matsushima E, Miyahara S, Miyakoshi H, Taguchi J, Chong KT, Takao Y, Fukuoka M, Matsuo K. Yano W, et al. Among authors: yoshisue k. Mol Cancer Ther. 2018 Aug;17(8):1683-1693. doi: 10.1158/1535-7163.MCT-17-0911. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748212

4

Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.

Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I. Takahashi K, et al. Among authors: yoshisue k. Biopharm Drug Dispos. 2018 Jan;39(1):38-46. doi: 10.1002/bdd.2110. Epub 2017 Dec 15. Biopharm Drug Dispos. 2018. PMID: 29055025

5

Effect of interfacial serum proteins on the cell membrane disruption induced by amorphous silica nanoparticles in erythrocytes, lymphocytes, malignant melanocytes, and macrophages.

Shinto H, Fukasawa T, Yoshisue K, Tsukamoto N, Aso S, Hirohashi Y, Seto H. Shinto H, et al. Among authors: yoshisue k. Colloids Surf B Biointerfaces. 2019 Sep 1;181:270-277. doi: 10.1016/j.colsurfb.2019.05.067. Epub 2019 May 27. Colloids Surf B Biointerfaces. 2019. PMID: 31153022

6

Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.

Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Chiba M. Yamamiya I, et al. Among authors: yoshisue k. Drug Metab Dispos. 2014 Sep;42(9):1485-92. doi: 10.1124/dmd.114.058008. Epub 2014 Jul 7. Drug Metab Dispos. 2014. PMID: 25002745

7

Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.

Yamamiya I, Yoshisue K, Matsushima E, Nagayama S. Yamamiya I, et al. Among authors: yoshisue k. Drug Metab Dispos. 2010 Aug;38(8):1267-76. doi: 10.1124/dmd.110.032797. Epub 2010 May 12. Drug Metab Dispos. 2010. PMID: 20463005

8

Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.

Yamashita F, Komoto I, Oka H, Kuwata K, Takeuchi M, Nakagawa F, Yoshisue K, Chiba M. Yamashita F, et al. Among authors: yoshisue k. Cancer Chemother Pharmacol. 2015 Aug;76(2):325-33. doi: 10.1007/s00280-015-2805-9. Epub 2015 Jun 18. Cancer Chemother Pharmacol. 2015. PMID: 26084259

9

Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.

Yoshino T, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N. Yoshino T, et al. Among authors: yoshisue k. Cancer Chemother Pharmacol. 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. Epub 2016 Dec 8. Cancer Chemother Pharmacol. 2017. PMID: 27933371 Clinical Trial.

10

The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.

Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y. Kato M, et al. Among authors: yoshisue k. Pharm Res. 2008 Aug;25(8):1891-901. doi: 10.1007/s11095-008-9607-2. Epub 2008 May 16. Pharm Res. 2008. PMID: 18483837

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

24 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year